Shares of Oragenics, Inc. (NYSE:OGEN) gained 1.29% to $0.93 on Tuesday. The share price is trading in a range of 0.91 – 0.94 (Price in Dollars).
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), uncovered the publication of a preclinical study using the lead compound from its lantibiotics program, OG716, in the peer reviewed journal, Antimicrobial Agents and Chemotherapy.
The preclinical study demonstrated that following oral administration of the maximum feasible dose of OG716 in hamster models, there were no observable toxicities nor observable side effects, nor was there any effect on intestinal motility. Treatment of animals infected with C. difficile resulted in a dose-dependant survival, and no recurrence at the upper dose tested. Further, researchers observed that the compound remained constrained only in the gastrointestinal tract. Lantibiotics, including OG716, are a novel class of peptide antibacterial compounds naturally produced by a variety of Gram-positive bacteria. Oragenics’ lantibiotic library offers a large pipeline for the development of novel antibiotics in several indications.
“The publication of this study offers additional validation for the safety and tolerability of our lantibiotic program, while simultaneously confirming the potential for our lead candidate for the treatment of CDAD,” stated Alan Joslyn, Ph.D., President and CEO of Oragenics, Inc. “There exists a dire need for new approaches to fighting antibiotic-resistant infections, and we believe the continued development of our lantibiotic program is one of those potential solutions. We look forward to providing continued updates on the development of OG716 as they become available.”
The stock exchanged hands 482,246 shares versus average trading capacity of 2.22M shares, while its shares’ total market worth is $27.43M. Oragenics, Inc. (NYSE:OGEN) shares were trading -77.84% below from the 52-week high price mark of $4.20 and +144.88% above from the 52-week price bottom of $0.38.
The company employs 12 people, over the last 12 months has generated revenue of $0.00 million and has a net income of $-10.00 million.
The company’s EPS growth in prior 5 years was -1.45%. In the liquidity ratio analysis; current ratio was 9.90 while debt to equity ratio was 0.03.
Oragenics institutional ownership is held at 11.70% while insider ownership was 6.89%. Its EPS was $-1.45 while outstanding shares of the company were 28.53 million. The Company’s Net profit margin was 0.00% while gross profit margin was 0.00%. OGEN last month stock price volatility remained 7.53%.
The stock is now trading at a distance of -1.37% from 20-day simple moving average. The company’s price sits -1.54% above from its 50-day moving average of $0.9109 and -7.85% far from the stock’s 200-day moving average which is $0.8520.
Oragenics, Inc. (NYSE:OGEN) currently has a PEG ratio of 0.00 where as its P/E ratio is 0.00. The company’s price to sales ratio for trailing twelve months is 0.00 and price to book ratio for most recent quarter is 1.53, whereas price to cash per share for the most recent quarter is 1.90. Oragenics, Inc. (NYSE:OGEN)’s price to free cash flow for trailing twelve months is 0.00. Its quick ratio for most recent quarter is 9.90 along with current ratio for most recent quarter of 9.90. Total debt to equity ratio of the company for most recent quarter is 0.03 whereas long term debt to equity ratio for most recent quarter is 0.00. Oragenics, Inc. (NYSE:OGEN) has a Return on Assets of -119.90%. The company currently has a Return on Equity of 0.00% and Return on Investment of 0.00%.